Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population-Based Cohort Study.

Huilin TangYing LuMichael S OkunWilliam T DonahooAdolfo Ramirez-ZamoraFei WangYu HuangMelissa J ArmstrongMikael SvenssonBeth A VirnigSteven T DeKoskyJiang BianJingchuan Guo

Published in: Movement disorders : official journal of the Movement Disorder Society (2024)

Among Medicare beneficiaries with T2D, the new use of GLP-1RAs was significantly associated with a decreased risk of PD compared to the new use of DPP4i. © 2024 International Parkinson and Movement Disorder Society.

Keyphrases

healthcare